The topic of treatment-free remission has not yet been established in AML, particularly with IDH inhibitors, but considering the duration of this patient’s remission and deep molecular clearance demonstrated by MRD PCR-techniques and scMRD (NGS-based), we question whether it may be a possibility. The gene discussed is IDH2; the disease is acute myeloid leukemia.